NeoGenomics, Inc. Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents, Period Increase (Decrease), Excluding Exchange Rate Effect
NeoGenomics, Inc. (NEO) reported Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents, Period Increase (Decrease), Excluding Exchange Rate Effect of -$14.08 million for the 6-month period ending 2026-06-30, per its 10-Q filed 2026-07-28.
Financial Statements › Cash Flow › Change in Cash
us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect · last filed 2026-07-28
- NeoGenomics, Inc. cash, cash equivalents, restricted cash and restricted cash equivalents, period increase (decrease), excluding exchange rate effect for the quarter ending 2026-03-31 was -$13.47M.
- NeoGenomics, Inc. cash, cash equivalents, restricted cash and restricted cash equivalents, period increase (decrease), excluding exchange rate effect for the quarter ending 2025-03-31 was -$20.82M.
- NeoGenomics, Inc. cash, cash equivalents, restricted cash and restricted cash equivalents, period increase (decrease), excluding exchange rate effect for the quarter ending 2024-03-31 was -$10.57M.
- NeoGenomics, Inc. cash, cash equivalents, restricted cash and restricted cash equivalents, period increase (decrease), excluding exchange rate effect for fiscal 2025 was -$207.39M, a 945.68% decline from fiscal 2024.
- NeoGenomics, Inc. cash, cash equivalents, restricted cash and restricted cash equivalents, period increase (decrease), excluding exchange rate effect for fiscal 2024 was $24.52M, a 69.08% decline from fiscal 2023.
- NeoGenomics, Inc. cash, cash equivalents, restricted cash and restricted cash equivalents, period increase (decrease), excluding exchange rate effect for fiscal 2023 was $79.31M.
- NeoGenomics, Inc. cash, cash equivalents, restricted cash and restricted cash equivalents, period increase (decrease), excluding exchange rate effect for fiscal 2022 was -$53.65M, a 181.04% decline from fiscal 2021.
| Period end | Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents, Period Increase (Decrease), Excluding Exchange Rate Effect 3 month | Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents, Period Increase (Decrease), Excluding Exchange Rate Effect 6 month | Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents, Period Increase (Decrease), Excluding Exchange Rate Effect 9 month | Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents, Period Increase (Decrease), Excluding Exchange Rate Effect 12 month |
|---|---|---|---|---|
| 2026-06-30 | -$14.08M 10-Q · filed 2026-07-28 | |||
| 2026-03-31 | -$13.47M 10-Q · filed 2026-04-28 | |||
| 2025-12-31 | -$207.39M 10-K · filed 2026-02-17 | |||
| 2025-09-30 | -$202.86M 10-Q · filed 2025-10-28 | |||
| 2025-06-30 | -$212.24M 10-Q · filed 2026-07-28 | |||
| 2025-03-31 | -$20.82M 10-Q · filed 2026-04-28 | |||
| 2024-12-31 | $24.52M 10-K · filed 2026-02-17 | |||
| 2024-09-30 | $19.50M 10-Q · filed 2025-10-28 | |||
| 2024-06-30 | $12.60M 10-Q · filed 2025-07-29 | |||
| 2024-03-31 | -$10.57M 10-Q · filed 2025-04-29 | |||
| 2023-12-31 | $79.31M 10-K · filed 2026-02-17 | |||
| 2022-12-31 | -$53.65M 10-K · filed 2025-02-18 | |||
| 2021-12-31 | $66.19M 10-K · filed 2024-02-20 | |||
| 2020-12-31 | $77.62M 10-K · filed 2023-02-24 | |||
| 2019-12-31 | $163.21M 10-K · filed 2022-02-25 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| 20/20 Biolabs, Inc. (AIDX) | United States | $0.005B |